Which hormone protocol yields healthier embryos for PCOS patients?

NCT ID NCT05326087

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two common ovarian stimulation protocols—PPOS (using a progesterone-like drug) and GnRH antagonist—in women with polycystic ovary syndrome (PCOS) who are undergoing preimplantation genetic testing (PGT-A). The goal is to see which method results in more genetically normal embryos. About 204 women aged 20-37 with PCOS will be randomly assigned to one of the two groups, and the main outcome is the rate of healthy (euploid) embryos.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Medroxyprogesterone acetate (MPA) and Cetrorelix (GnRH antagonist)
What this could lead to
If this trial succeeds, it could show that one stimulation method leads to more genetically normal embryos, potentially improving IVF success for women with PCOS.
What could go wrong
This is a phase 3 trial, but it only compares two existing methods—neither is new. The results may not apply to all women with PCOS, and the primary outcome is embryo health, not live birth.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GNRH ANTAGONIST are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

More trials for these conditions

Other studies related to the condition(s) this trial covers.